Supernus Pharmaceuticals (SUPN) Net Margin (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Net Margin of 26.65% for Q2 2026, down 4024.0% year-over-year from 0.68% in Q2 2025, and down 1263.72% on a QoQ basis from 1.95% in Q4 2025.
Supernus Pharmaceuticals (SUPN) Net Margin (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Net Margin for 16 years, with the latest figure at 26.65% in Q2 2026.
- Net Margin for Q2 2026 came in at 26.65%, down 4024.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 13.65% (down 2336.0% YoY), and the FY2025 annual result was 5.36%, down 1652.0% from the prior year.
- Net Margin eased to 26.65% in Q2 2026, from 1.95% in the prior quarter.
- Over five years, Net Margin peaked at 21.91% in Q3 2024 and troughed at 26.65% in Q2 2026.
- A 5-year average of 2.04% and a median of 0.99% in 2022 frame the typical range for Net Margin.
- The widest annual swing landed in 2024, when Net Margin jumped 3232 bps; it then tumbled 4540 bps in 2025.
- A 5-year view of Net Margin shows it stood at 15.23% in 2022, then tumbled by 95 bps to 0.72% in 2023, then soared by 1135 bps to 8.83% in 2024, then tumbled by 122 bps to 1.95% in 2025, then slumped by 1264 bps to 26.65% in 2026.
- Per Business Quant data, the three most recent Net Margin figures were 26.65% in Q2 2026, 1.95% in Q4 2025, and 23.49% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -13.91% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 9.28% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 42.51% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -3.16% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 15.06% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.95% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.38 Bn | 185.39 Mn | -26.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.65% |
| Dec 31, 2025 | -1.94% |
| Sep 30, 2025 | -23.49% |
| Jun 30, 2025 | 13.60% |
| Mar 31, 2025 | -7.89% |
| Dec 31, 2024 | 8.80% |
| Sep 30, 2024 | 21.94% |
| Jun 30, 2024 | 11.82% |
| Mar 31, 2024 | 0.10% |
| Dec 31, 2023 | 0.72% |
| Sep 30, 2023 | -10.38% |
| Jun 30, 2023 | -0.61% |
| Mar 31, 2023 | 11.02% |
| Dec 31, 2022 | 15.24% |
| Sep 30, 2022 | 0.99% |
| Jun 30, 2022 | 4.63% |
| Mar 31, 2022 | 16.80% |
| Dec 31, 2021 | 1.54% |
| Sep 30, 2021 | 14.52% |
| Jun 30, 2021 | 16.79% |